Research Spotlight: Nanomedicines for HIV therapy

Marco Siccardi, Philip Martin, Tom O. McDonald, Neill J. Liptrott, Marco Giardiello, Steve Rannard, Andrew Owen

Research output: Contribution to journalArticlepeer-review


Heterogeneity in response to HIV treatments has been attributed to several causes including variability in pharmacokinetic exposure. Nanomedicine applications have a variety of advantages compared with traditional formulations, such as the potential to increase bioavailability and specifically target the site of action. Our group is focusing on the development of nanoformulations using a closed-loop design process in which nanoparticle optimization (disposition, activity and safety) is a continuous process based on experimental pharmacological data from in vitro and in vivo models. Solid drug nanoparticles, polymer-based drug-delivery carriers as well as nanoemulsions are nanomedicine options with potential application to improve antiretroviral deployment.
Original languageEnglish
Pages (from-to)153-156
Number of pages4
JournalTherapeutic delivery
Issue number2
Early online date23 Jan 2013
Publication statusPublished - Feb 2013


Dive into the research topics of 'Research Spotlight: Nanomedicines for HIV therapy'. Together they form a unique fingerprint.

Cite this